Stock Price Quote

LOTUS EYE HOSPITAL AND INSTITUTE LTD.

NSE : LOTUSEYEBSE : 532998ISIN CODE : INE947I01017Industry : Hospital & Healthcare ServicesHouse : Private
BSE76.35-2.43 (-3.08 %)
PREV CLOSE ( ) 78.78
OPEN PRICE ( ) 79.45
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 12383
TODAY'S LOW / HIGH ( )75.85 79.50
52 WK LOW / HIGH ( )44.1 110.9
NSE76.19-2.45 (-3.12 %)
PREV CLOSE( ) 78.64
OPEN PRICE ( ) 78.64
BID PRICE (QTY) 76.19 (7)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 120305
TODAY'S LOW / HIGH( ) 76.01 80.90
52 WK LOW / HIGH ( )48.5 111
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 14-03 1997
Management Info
Kavetha Sundaramoorthy - Chairman Sangeetha Sundaramoorthy - Managing Director
Registered Office

Address S F No 770 / 12,Civil Aerodrome Post,Avinashi Road,
Coimbatore,
Tamil Nadu-641014

Phone 0422 4229900 / 99

Email lotuseye@eth.net / info@lotuseye.org

Website www.lotuseye.org

Registrars Details
Link Intime India Pvt Ltd.
Surya, 35 Mayflower Avenue,Behind Senthil Nagar,Sowripalayam Road,Coimbatore
Listing : BSE, NSE

NEWS

28Aug Lotus Eye Hospital And Institute infor
Lotus Eye Hospital And Institute has informed that the exchange has rece..
28Jun Lotus Eye Hospital And Institute infor
Lotus Eye Hospital And Institute has informed that trading window shall..
28May Lotus Eye Hospital And Institute infor
Lotus Eye Hospital And Institute has informed that it enclosed the copy..
20Apr Lotus Eye Hospital & Institute informs
Pursuant to the provisions of SEBI Circular SEBI/HO/DDHS/CIR/P/2018/144..
16Apr Lotus Eye Hospital and Institute infor
Pursuant to Regulation 40(10) of SEBI (LODR) Regulations, 2015, Lotus Ey..

Financials

in Millions
QTR Jun 24 ANNUAL 24
Net Profit6.2329.16
Gross Profit 8.56 40.15
Operating Profit 19.778.34
Net Sales 128.91482.1

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Dr. Lal Pathlabs (BSE)
peergroup  3396.45 (0.80%)
M.Cap ( in Cr)28385.58
Krishna Inst.Medi (BSE)
peergroup  2663.40 (0.90%)
M.Cap ( in Cr)21314.60
Kovai Medical Center (BSE)
peergroup  5508.90 (0.38%)
M.Cap ( in Cr)6027.98
Indraprastha Medical (BSE)
peergroup  458.25 (3.89%)
M.Cap ( in Cr)4200.92
RainbowChildrenS Med (BSE)
peergroup  1329.30 (1.23%)
M.Cap ( in Cr)13499.26

Shareholding Pattern

NON-INSTITUTION 59.76%
PROMOTERS 40.24%
MUTUAL FUNDS/UTI 0%
FI/BANKS/INSURANCE 0%
GOVERNMENT 0%
FII 0%

About Lotus Eye Hospital And Institute Ltd.

Lotus Eye Hospital And Institute Ltd. was incorporated in the year 1997. Its today's share price is 76.35. Its current market capitalisation stands at Rs 158.78 Cr. In the latest quarter, company has reported Gross Sales of Rs. 482.1 Cr and Total Income of Rs.495.13 Cr. The company's management includes M Achuth Menon, Perumalsamy Mahendran, Karthik Veeramani, S Natesan, M Alagiriswamy, Yogesh Shah, DR Kaarthikeyan, KS ramalingam, Sangeetha Sundaramoorthy, Kavetha Sundaramoorthy.

It is listed on the BSE with a BSE Code of 532998 , NSE with an NSE Symbol of LOTUSEYE and ISIN of INE947I01017. It's Registered office is at S F No 770 / 12,Civil Aerodrome Post,Avinashi RoadCoimbatore-641014, Tamil Nadu. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are Anbarasu & Jalapathi, Vekam & Associates

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.